Chief Investigators: S Miller, G Jenkins, CI Fahey.
Funding: NHMRC 1081516, (2015-2018) $708,882.
Aims: A preclinical trial is isolating cell types from cord blood and testing their efficacy in different scenarios of brain injury. The optimal timing of cell therapy is being explored.
New knowledge: This trial will identify what roles the different stem cell components of cord blood have in protecting from different types of asphyxial injury using an established animal model and the best time to deliver them. This will allow efficient progress to human trials.